Nuclea Files for FDA Approval of Breast Cancer, Prostate Cancer Assays | GenomeWeb

By a GenomeWeb staff reporter

This article has been updated from a previous version, which incorrectly stated that the company had filed for premarket approval of its assays.

SAN FRANCISCO (GenomeWeb News) – Nuclea Biotechnologies said on Wednesday that has filed premarket IDE filings with the US Food and Drug Administration for its breast cancer and prostate cancer assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.